

Ramapo College Immunization Requirements

DUE DATE

Fall Semester Start: July 31st

Spring Semester Start: January 2nd

IMMUNIZATION POLICY

Failure to complete health requirements will result in a registration hold.

All registered students are required to submit this form if you are taking classes (in person, online, or virtual).

REQUIRED IMMUNIZATION FORMS

- 1. Take this packet to your health care provider to be completed, signed, and stamped. This form does not have to be used; an official immunization record from your doctor, employer, military, hospital, or previous school can be submitted. Please make sure that all the required information is provided if you are not using this form.
- 2. Once you have obtained your immunization documents, please submit your immunization forms to Health Services via email (immunize@ramapo.edu) or fax at 201-684-7534 or 201-684-7974.
- 3. If you are age 31 or older at the time of admission to Ramapo College of New Jersey, you are exempt from the immunization requirements under NJ State Law.





IMMUNIZATION RECORD

Ramapo Student ID:
R00

PART 1: COMPLETED BY THE STUDENT. All information must be printed legibly or form cannot be								
processed.								
Last Na	me:	First Name:			Middle Initial:			
DOB:		Start Date: Year:	Start Date:Fall Spring Year:		Cell Number:			
Full-time	e (12 or more credits) YesNo	Resident Co	dent Commuter		Residing in the U.S. with a student visaYes No			
PART	2: TO BE COMPLETED AND							
A.	TUBERCULOSIS—PLEASE SEE ATTACHMENT 1 TO COMPLY WITH THIS REQUIREMENT. ALL STUDENTS MUST UPLOAD ATTACHMENT 1 ALONG WITH THIS FORM.							
B.	MMR (Measles, Mumps, Rubella)—Two doses of vaccine OR titers showing immunity (COPY OF LAB REPORT REQUIRED).							
	1st dose (given at or after 1st birthda	y):		2 nd dose):			
C.	HEPATITIS B—Completion of three doses of vaccine OR titers showing immunity (COPY OF LAB REPORT REQUIRED). Note: Negative titers will require the student to repeat the series with 3 doses of Hep B.							
	1 st dose date: 2	nd dose: 3rd dose		÷:				
D.	MENINGOCOCCAL ACWY—One dose received AT OR AFTER AGE 16. REQUIRED for all students who are 18 years of age and younger <i>OR</i> any student residing on campus regardless of age. Visit https://www.ramapo.edu/health/meningitis-information/ for more information on Meningitis.							
	Dose received at or after age 16:		Previous dose received at age 10-15:					
Е	RECOMMENDED: MENINGOCOC	CAL B (please c	ircle Trumenb	a or Bexs	sero):			
	1 st Dose:	2 nd Dose:		3 rd [Dose:			
	,			<u>,</u>				
F.	HEALTH CARE EXAMINER'S STATEMENT: I HAVE VERIFIED THAT THE INDIVIDUAL I HAVE EXAMINED IS THE NAMED INDIVIDUAL ON THIS FORM AND THAT THE ABOVE TESTS/VACCINATIONS WERE PERFORMED IN THIS OFFICE/LABORATORY, OR I HAVE REVIEWED ANY DOCUMENTATION RELATIVE TO THE STUDENT'S IMMUNIZATION RECORD.							
	License #:		Phone #:					
	Signature of Healthcare Examiner:	,			Date:			
PART 3: TO BE SIGNED BY THE STUDENT—FORM CANNOT BE PROCESSED WITHOUT STUDENT SIGNATURE.								
Student	Signature:		Ramapo Student ID:					
The information provided on this form is correct. I understand that failure to complete this form correctly may jeopardize my student standing at Ramapo College. I will submit the form using the directions provided on information sheet.								

PLEASE VISIT https://www.ramapo.edu/health/immunization-info/ FOR ANY UPDATES REGARDING RAMAPO COLLEGE'S IMMUNIZATION REQUIREMENTS.



TOOL FOR INSTITUTIONAL USE-ATTACHMENT 1

Part I: Tuberculosis (TB) Screening Questionnaire (to be completed by incoming students)

Please answer the following of	questions (1 through 6):		
1. Have you ever had close cor	ntact with persons known or suspen	cted to have active TB disease?	Yes No
2. Were you born in one of the	countries or territories listed below	that have a high incidence of active TE	3 disease?
(If yes, please CIRCLE the cou		· ·	☐ Yes ☐ No
Algeria	Djibouti	Malawi	Senegal
Angola	Dominican Republic	Malaysia	Sierra Leone
Argentina	Ecuador	Maldives	Singapore
Armenia	El Salvador	Mali	Solomon Islands
Azerbaijan	Equatorial Guinea	Marshall Islands	Somalia
Bangladesh	Eritrea	Mauritania	South Africa
Belarus	Eswatini	Mexico	South Sudan
Belize	Ethiopia	Micronesia	Sri Lanka
Benin	Fiji	Mongolia	Sudan
Bhutan	Gabon	Morocco	Suriname
Bolivia (Plurinational State of)	Gambia	Mozambique	Tajikistan
Bosnia and Herzegovina	Georgia	Myanmar	Thailand
Botswana	Ghana	Namibia	Timor-Leste
Brazil	Guatemala	Nauru	Togo
Brunei Darussalam	Guinea	Nepal	Tunisia
Burkina Faso	Guinea-Bissau	Nicaragua	Turkmenistan
Burundi Caba Marda	Guyana	Niger	Tuvalu
Cabo Verde	Haiti	Nigeria	Uganda Ukraine
Cambodia Cameroon	Honduras India	Niue Pakistan	United Republic of Tanzania
Central African Republic	Indonesia	Palau	Uruguay
Chad	Iraq	Panama	Uzbekistan
China	Kazakhstan	Papua New Guinea	Vanuatu
China, Hong Kong SAR	Kenya	Paraguay	Venezuela (Bolivarian
China, Macao SAR	Kiribati	Peru	Republic of)
Colombia	Kyrgyzstan	Philippines	Vietnam
Comoros	Lao People's Democratic	Qatar	Yemen
Congo	Republic	Republic of Korea	Zambia
Côte d'Ivoire	Lesotho	Republic of Moldova	Zimbabwe
Democratic People's	Liberia	Romania	
Republic of Korea	Libya	Russian Federation	
Democratic Republic of the	Lithuania	Rwanda	
Congo	Madagascar	Sao Tome and Principe with average incidence rates of ≥ 20 cases per 100,000 pc	apulation
3. Have you resided in or travel		or territories listed above for a period of	
 Have you been a resident an term care facilities, and homele 		gate settings (e.g., correctional facilities	s, long- Yes No
5. Have you been a volunteer o TB disease?	or health care worker who served c	lients who are at increased risk for activ	/e Yes No
		nat may have an increased incidence of ved, low-income, or abusing drugs or a	
		College requires that you receive TB should be discussed with a health care	
If the answer to all of the abo	ve questions is NO, no further tes	sting or further action is required. You	may stop here.
Student's printed name and signature (required):		Date:	



Part II: Clinical Assessment to be completed by Health Care Provider

Clinicians should review and verify the information in Part I. Persons who answered NO to all questions in Part I do not need further testing. Persons who answered YES to any of the questions in Part I are candidates for either the Mantoux tuberculin skin test (TST) or the Interferon Gamma Release Assay (IGRA), unless a previous positive test has been documented.

Ha	been documented.						
	 History of a positive TB skin test or IGRA blood test? (If yes, document below.) 						
	▶ History of BCG vaccination? (If yes, consider IGRA if possible.) □ Yes □ No						
1. TB SYMPTOM CHECK							
	Does the student have signs or symptoms of active pulmonary tuberculosis disease?						
	If No, proceed to 2 or 3.						
If Yes, check below:							
	 Cough (especially if lasting for 3 weeks or longer) with or without sputum production 						
	 Coughing up blood (hemoptysis) 						
	o Chest pain						
	 Loss of appetite 						
	 Unexplained weight loss 						
	 Night sweats 						
o Fever							
	Proceed with additional evaluation to exclude active tuberculosis disease, including tuberculin skin testing,						
	chest X-ray, and sputum evaluation as indicated.						
2.	TUBERCULIN SKIN TEST (TST): MUST BE PERFORMED IN THE UNITED STATES (IF CURRENTLY LIVING						
	OUTSIDE OF THE UNITED STATES, GO TO #3).						
	(TST result should be recorded as actual millimeters [mm] of induration, transverse diameter; if no induration,						
	write "0." The TST interpretation should be based on mm of induration as well as risk factors.)**						

**INTERPRETATION GUIDELINES

Result: mm of induration

Date Given:___/___/

>5 mm is positive:

- Recent close contacts of an individual with infectious TB
- Persons with fibrotic changes on a prior chest X-ray, consistent with past TB disease
- Organ transplant recipients and other immunosuppressed persons (including receiving equivalent of >15mg/d of prednisone for >1 month)

Date Read: ____/____

**Interpretation: positive negative

HIV-infected persons

> 10 mm is positive:

- Recent arrivals to the U.S. (<5 years) from high-prevalence areas or who resided in one for a significant
 amount of time (The significance of the travel exposure should be discussed with a health care provider
 and evaluated.)
- Injection drug users
- Mycobacteriology laboratory personnel
- Residents, employees, or volunteers in high-risk congregate settings
- Persons with medical conditions that increase the risk of progression to TB disease, including silicosis, diabetes mellitus, chronic renal failure, certain types of cancer (leukemias and lymphomas, cancers of the head, neck, or lung), gastrectomy or jejunoileal bypass and weight loss of at least 10% below ideal body weight.

>15 mm is positive:

 Persons with no known risk factors for TB who, except for certain testing programs required by law or regulation, would otherwise not be tested.



3.	STATES BUT LAE		•	,	MPLETED	OUTSIDE	OF THE UN	MILED
	Date Obtained:	_//	. (circle method)	QFT-GIT	T-Spot	other	
	Result: negative	positive	indeterminate_	borderline_	(T-S	spot only)		
4.	CHEST X-RAY: R	EQUIRED IF	TST OR IGRA IS	POSITIVE (Rad	liology repo	ort is req	uired in Eng	ılish).
	Note: a single Date of chest X-ray	y:/			Result: norm	nal a	bnormal	-
	rt III: Management							
	students with a posi commendation to be		•			•		
	at increased risk of							
po	ssible.				·			
	Infected with							
	-		. tuberculosis (wi		•		Chartin abou	
			adequately treate th prior TB diseas		nciuaing per	sons with	i fibrotic char	iges on chest
			essive therapy, s		crosis factor	r-alpha (T	NF) antagon	ists. systemic
			nt to/greater than					
			ransplantation					
	 Diagnosed lung 	l with silicosis,	diabetes mellitus	s, chronic renal f	ailure, leuke	emia, or c	ancer of the l	nead, neck, or
	Have had	a gastrectomy	or jejunoileal by	oass				
	•		their ideal body w	•				
	 Cigarette s 	smokers and p	ersons who abus	e drugs and/or	alcohol			
	Student agrees to	receive treatm	ent					
	Student declines tr	eatment at thi	s time					
lealth	Care Professional							
ignat	ure:				Date:			_

